Related Experiment Videos

Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention

Maureen McMahon1, Bevra H Hahn, Brian J Skaggs

  • 1Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA. mmcmahon@mednet.ucla.edu

Expert Review of Clinical Immunology
|March 24, 2011
PubMed

Insights

Patients with systemic lupus erythematosus (SLE) face higher cardiovascular risks. Inflammation and immune responses, not just lipids, drive atherosclerosis in SLE, suggesting new treatment targets.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Rheumatology

Background:

  • Systemic lupus erythematosus (SLE) patients exhibit a significantly elevated risk of cardiovascular events, primarily driven by atherosclerosis.
  • Conventional cardiac risk factors inadequately account for the heightened atherosclerosis risk observed in SLE patients.
  • Emerging research indicates that atherosclerotic plaque development in SLE is predominantly influenced by inflammatory and immunological processes, challenging the traditional lipid-centric view.

Purpose of the Study:

  • To highlight the immunological underpinnings of atherosclerosis in systemic lupus erythematosus.
  • To underscore the limitations of current atherosclerosis prevention strategies in SLE.
  • To propose future therapeutic avenues targeting immune responses in SLE-related cardiovascular disease.

Main Methods:

  • Review of current literature on atherosclerosis pathogenesis in SLE.
  • Analysis of the role of inflammation and immune responses in plaque formation.
  • Evaluation of existing and potential preventive strategies for cardiovascular events in SLE.

Main Results:

  • Atherosclerotic plaque in SLE is significantly driven by inflammation and active immunological responses.
  • Traditional cardiovascular risk factor management is insufficient for SLE patients.
  • Inflammation and immune dysregulation are key contributors to accelerated atherosclerosis in SLE.

Conclusions:

  • Future prevention of atherosclerosis in SLE should incorporate therapies targeting aberrant immunological pathways.
  • Understanding the immunopathogenesis of atherosclerosis is crucial for mitigating cardiovascular risk in SLE.
  • Novel therapeutic strategies may involve modulating immune responses to prevent plaque formation and cardiovascular events in SLE.

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...